Close Menu

NEW YORK – The US Food and Drug Administration announced Tuesday that it has authorized Vela Diagnostics' next-generation sequencing-based HIV-1 drug resistance mutation assay for marketing through its de novo premarket review pathway.

The agency said the test — called the Sentosa SQ HIV Genotyping Assay — is the first HIV drug resistance assay utilizing NGS technology that the FDA has authorized for marketing in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.